These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 33064340)

  • 1. Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects.
    Criscuolo E; Diotti RA; Strollo M; Rolla S; Ambrosi A; Locatelli M; Burioni R; Mancini N; Clementi M; Clementi N
    J Med Virol; 2021 Apr; 93(4):2160-2167. PubMed ID: 33064340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively.
    Bonelli F; Sarasini A; Zierold C; Calleri M; Bonetti A; Vismara C; Blocki FA; Pallavicini L; Chinali A; Campisi D; Percivalle E; DiNapoli AP; Perno CF; Baldanti F
    J Clin Microbiol; 2020 Aug; 58(9):. PubMed ID: 32580948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
    Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
    J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
    Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
    Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-Head Comparison of Two SARS-CoV-2 Serology Assays.
    Merrill AE; Jackson JB; Ehlers A; Voss D; Krasowski MD
    J Appl Lab Med; 2020 Nov; 5(6):1351-1357. PubMed ID: 32717056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points to IgM as the Achilles heel.
    Mboumba Bouassa RS; Péré H; Tonen-Wolyec S; Longo JD; Moussa S; Mbopi-Keou FX; Mossoro-Kpinde CD; Grésenguet G; Veyer D; Bélec L
    J Med Virol; 2021 Apr; 93(4):2196-2203. PubMed ID: 33107601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Ferrer J; Forqué L; Costa R; de la Asunción CS; Huntley D; Gozalbo-Rovira R; Buesa J; Giménez E; Rodríguez-Díaz J; Geller R; Navarro D
    J Med Virol; 2021 Apr; 93(4):2301-2306. PubMed ID: 33236799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies.
    Rychert J; Couturier MR; Elgort M; Lozier BK; La'ulu S; Genzen JR; Straseski JA; Delgado JC; Slev PR
    J Appl Lab Med; 2021 Apr; 6(3):614-624. PubMed ID: 33064790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet.
    Krüttgen A; Cornelissen CG; Dreher M; Hornef MW; Imöhl M; Kleines M
    J Virol Methods; 2021 Jan; 287():113978. PubMed ID: 32979407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
    Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
    PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays.
    Kohmer N; Westhaus S; Rühl C; Ciesek S; Rabenau HF
    J Clin Virol; 2020 Aug; 129():104480. PubMed ID: 32505777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients.
    Pflüger LS; Bannasch JH; Brehm TT; Pfefferle S; Hoffmann A; Nörz D; van der Meirschen M; Kluge S; Haddad M; Pischke S; Hiller J; Addo MM; Lohse AW; Schulze Zur Wiesch J; Peine S; Aepfelbacher M; Lütgehetmann M
    J Clin Virol; 2020 Sep; 130():104549. PubMed ID: 32763809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical diagnostic performance evaluation of five immunoassays for antibodies to SARS-CoV-2 diagnosis in a real-life routine care setting.
    Akyala AI; Awayimbo JR; Ogo AC; Chima NJ; Billyrose OMA; Engom AOG
    Pan Afr Med J; 2021; 39():3. PubMed ID: 34178231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays.
    Weidner L; Gänsdorfer S; Unterweger S; Weseslindtner L; Drexler C; Farcet M; Witt V; Schistal E; Schlenke P; Kreil TR; Jungbauer C
    J Clin Virol; 2020 Aug; 129():104540. PubMed ID: 32652475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area.
    Cassaniti I; Percivalle E; Sarasini A; Cambiè G; Vecchio Nepita E; Maserati R; Ferrari A; Corcione A; Di Martino R; Bonetti A; Di Napoli A; Ferrari G; Baldanti F
    Clin Microbiol Infect; 2021 Jun; 27(6):914.e1-914.e4. PubMed ID: 33677083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.
    Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E
    J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of SARS-CoV-2 IgG antibody response in PCR positive patients: Comparison of nine tests in relation to clinical data.
    Naaber P; Hunt K; Pesukova J; Haljasmägi L; Rumm P; Peterson P; Hololejenko J; Eero I; Jõgi P; Toompere K; Sepp E
    PLoS One; 2020; 15(10):e0237548. PubMed ID: 33108380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.